Printer Friendly

GENMAB/IMMUNEX TO DISCOVER AND DEVELOP CANCER ANTIBODY.

Genmab A/S (CSE: GEN and Neuer Markt: GE9D), Copenhagen, Denmark, has entered a new collaborative agreement with Immunex Corporation (Nasdaq: IMNX) to discover and develop a fully human antibody against a proprietary Immunex cancer target. Initially, this new antibody is expected be used to treat lymphoma.

Under the terms of the collaboration, Genmab will be responsible for creating the antibody, to be called HuMax-Lymphoma, and for developing it through Phase II clinical trials. Immunex retains an exclusive option for the product through Phase II. Should Immunex exercise its option, Immunex would complete the clinical development of HuMax-Lymphoma and would pay Genmab a license fee, milestones and share profits upon commercialization. Alternately, Genmab will retain the right to continue to develop and potentially commercialize the antibody and would pay milestone fees and royalties to Immunex.

HuMax-Lymphoma will target the IL-15 receptor, which is covered by a broad Immunex patent estate. This receptor is found on a number of tumor types, including T cell and Natural Killer cell lymphomas, as well as multiple myeloma. The cytokine IL-15 contributes to cell growth and proliferation and helps prevent programed cell death (apoptosis). Blocking tumor receptors for IL-15 with HuMax-Lymphoma has the potential to result in very specifically targeted anti-cancer therapy.

HuMax-Lymphoma will be the second product to result from the Immunex-Genmab collaboration. The first product, HuMax-IL15 to treat rheumatoid arthritis, is currently in Phase I/II clinical trials.

"Genmab is delighted to expand its work with Immunex," said Lisa N. Drakeman, Ph.D. "We are also hopeful that HuMax-Lymphoma will bring a much needed new cancer treatment to the many thousands of patients suffering from these aggressive forms of cancer ."

About Genmab A/S

Genmab A/S is a biotechnology company that creates and develops fully human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, rheumatoid arthritis and other inflammatory conditions, and intends to assemble a broad portfolio of new therapeutic products arising from research into the human genome. At present, Genmab's commercial opportunities are based upon research conducted at leading international companies, including Roche, Immunex Corporation, Oxford GlycoSciences Ltd., Medarex, Inc., deCODE Genetics, Sequenom, Inc., Eos Biotechnology Inc., and Glaucus Proteomics B.V., as well as in its own laboratories. A broad alliance provides Genmab with access to Medarex's array of proprietary technologies, including the UltiMAb platform for the rapid creation and development of fully human antibodies to virtually any disease target.

For more information, http://visit www.genmab.com.
COPYRIGHT 2001 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Comment:GENMAB/IMMUNEX TO DISCOVER AND DEVELOP CANCER ANTIBODY.
Publication:Worldwide Biotech
Geographic Code:4EUDE
Date:Nov 1, 2001
Words:418
Previous Article:HEALTH CANADA APPROVES NOVARTIS ORAL CANCER DRUG.
Next Article:BAYER SUBMITS VARDENAFIL NDA FOR ERECTILE FUNCTION.
Topics:


Related Articles
New anticancer strategy targets gene.
(Anti-) septic strategies; new drugs hold promise for treating life-threatening bacterial infections.
GENMAB/ROCHE ANNOUNCE BROAD ANTIBODY DEVELOPMENT COLLABORATION.
SEATTLE GENETICS LICENSES PROACTA'S CELL-KILLING DRUGS.
CAMBRIDGE ANTIBODY TECHNOLOGY/AMGEN RESTRUCTURE AGREEMENT.
ROCHE SELECTS TWO GENMAB ANTIBODIES AS CLINICAL CANDIDATES.
ABLYNX AND GENENCOR FORM ONCOLOGY COLLABORATION.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |